HONG KONG – Sinovac Biotech Ltd., China's leading vaccine maker, is in the midst of a go-private transaction that has morphed into a heated bidding war.
HONG KONG – Sinovac Biotech Ltd., China's leading vaccine maker, is in the midst of a go-private transaction that has morphed into a heated bidding war.
HONG KONG – Tessa Therapeutics Pte. Ltd. stumbled upon a biomarker, which it contended could make a huge difference in predicting patient reaction to treatment and survival rates. Tessa's Chief Scientific Officer John Connolly said, "The biomarker can reveal how a patient responds to cancer treatment and it can be used to predict the patient's survival rate. It works based on the protein signature from myeloid-derived suppressor cells [MDSC]."
HONG KONG – Tessa Therapeutics Pte. Ltd. stumbled on to a biomarker, which it contended could make a huge difference in predicting patient reaction to treatment and survival rates.
HONG KONG – CSL Ltd. has bought a majority stake in China's Wuhan Zhong Yuan Ruide Biological Products Co. Ltd. in a $352 million deal that should make the Australian biotech company a market leader.
HONG KONG – CSL Ltd. has bought a majority stake in China’s Wuhan Zhong Yuan Ruide Biological Products Co. Ltd. in a $352 million deal that should make the Australian biotech company a market leader.
